GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (XSWX:ATLNE) » Definitions » Inventories, Other

Actelion (XSWX:ATLNE) Inventories, Other : CHF133 Mil (As of Mar. 2017)


View and export this data going back to . Start your Free Trial

What is Actelion Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Actelion's other inventories for the quarter that ended in Mar. 2017 was CHF133 Mil.

Actelion's quarterly other inventories declined from Sep. 2016 (CHF120 Mil) to Dec. 2016 (CHF0 Mil) but then increased from Dec. 2016 (CHF0 Mil) to Mar. 2017 (CHF133 Mil).


Actelion Inventories, Other Historical Data

The historical data trend for Actelion's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Inventories, Other Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.57 - 120.33 - 132.57

Actelion Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Actelion (XSWX:ATLNE) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (XSWX:ATLNE) Headlines

No Headlines